The clinical features of NBIA range from rapid global neurodevelopmental regression in infancy to mild parkinsonism with minimal cognitive impairment in adulthood, with wide variation seen between and within the specific NBIA sub-type.
Human germline genome editing may prove to be especially poignant for members of the rare disease community, many of whom are diagnosed with monogenic dise